Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have received a consensus rating of “Hold” from the thirty brokerages that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $469.27.

A number of analysts recently commented on the company. BTIG Research reiterated a “buy” rating and set a $520.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. BMO Capital Markets set a $444.00 price target on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Monday, November 27th. Citigroup lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $480.00 to $380.00 in a report on Friday, December 1st. Piper Jaffray Companies reissued a “buy” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 28th.

Regeneron Pharmaceuticals (NASDAQ REGN) traded up $0.25 during mid-day trading on Friday, hitting $371.53. The stock had a trading volume of 665,000 shares, compared to its average volume of 772,900. Regeneron Pharmaceuticals has a 52-week low of $340.09 and a 52-week high of $543.55. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $40,310.00, a PE ratio of 33.74, a P/E/G ratio of 1.43 and a beta of 1.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, beating analysts’ consensus estimates of $3.83 by $0.16. The company had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.13 earnings per share. analysts expect that Regeneron Pharmaceuticals will post 13.55 EPS for the current year.

Large investors have recently bought and sold shares of the stock. Fieldpoint Private Securities LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $130,000. Steward Partners Investment Advisory LLC lifted its position in shares of Regeneron Pharmaceuticals by 495.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 307 shares in the last quarter. Virtu KCG Holdings LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $206,000. Vident Investment Advisory LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $200,000. Finally, People s United Financial Inc. lifted its position in shares of Regeneron Pharmaceuticals by 656.7% in the second quarter. People s United Financial Inc. now owns 454 shares of the biopharmaceutical company’s stock worth $223,000 after buying an additional 394 shares in the last quarter. Institutional investors own 66.82% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-receives-469-27-consensus-target-price-from-brokerages/1818514.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.